Bitopertin was awarded the Commissioner’s National Priority Review Voucher (CNPV) and NDA is currently under FDA reviewUpdated data from the Phase 2 study of DISC-0974 in patients with myelofibrosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback